https://www.selleckchem.com/products/trolox.html
imilar 1-year patency rates, a conclusive finding of superiority was judged to be infeasible, and the trial was stopped for futility. Current evidence does not demonstrate sufficiently large benefit of heparin-bonded polytetrafluoroethylene over standard polytetrafluoroethylene for dialysis access to justify higher cost. Given similar 1-year patency rates, a conclusive finding of superiority was judged to be infeasible, and the trial was stopped for futility. In intraductal papillary mucinous neoplasm, a mural nodule ≥5 mm is an importan